Significance of total and lipid bound sialic acid in serum and urine as markers for bladder cancer

The reliability of serum total sialic acid [TSA], serum lipid bound sialic acid [LSA]. and urinary sialic acid / creatinine ratio [TSA / Cr. ratio] as markers for bladder cancer for grading, staging and follow-up purposes was evaluated in 10 healthy controls and 70 patients with bladder cancer, 25 of them with superficial tumors were evaluated after treatment with TUR for follow up. We found that TSA. LSA and TSA / Cr. ratio levels were significantly higher in patients with bladder cancer [56.9 +/- 8.9 mg /dl, 22.3 +/- 2.3 mg /dl and 37.2 +/- 16.1 ug/mg creatinine respectively] than controls [48.8 +/- 7.1 mg/dl, 16.9 +/- 0.6mg /dl and 11.9 +/- 5.1 ug /mg creatinine respectively]. There was no significant difference between grade 1,11 and III also between stage Ta, T1 and T2 and stage T3 and T4 bladder cancer patients regarding LSA and TSA, but there was a significant difference between these grades and stages regarding urinary TSA / Cr. ratio [20.1 +/- 16.1. 40.6 +/- 14.4 and 47.8 +/- 11.9 up / mg creatinine in grade I, II and III respectively and 32.1 +/- 12.1. 46.4 +/- 15.1 ug/mg creatinine in stage Ta. T1 and T2 and stage T3 and T4 respectively]. These findings suggest that TSA and LSA can't be used for grading and staging of bladder cancer patients. but urinary TSA / Cr. ratio can be used for grading and staging of these patients. On comparison of supeificial bladder cancer patients before and after treatment regarding the studied parameters, we found marked drop of urinary TSA/Cr. ratio in post-treatment patients [36.2 +/- 15.1 ug/mg creatinine before treatment versus 17.5 +/- 5.3 ug/mg creatinine after treatment] in contrary with serum TSA and LSA. We conclude that: urine can be used as easily available physiologic fluid for evaluation of TSA / Cr. ratio by an easy, inexpensive, photometeric method as a marker for bladder cancer for grading, staging and follow-up of treatment in patients with bladder cancer

Atrial natriuretic peptide in bronchial asthma in children

The hormone atrial natriuretic peptide [ANP] causes bronchodilation and partially protects against direct and indirect bronchial challenges in patients with asthma. The present study was carried out to determine the role of ANP in bronchial asthma in children. Twenty asthmatic children with age ranged from 1.5 to 11 years old were subjected to clinical laboratory and radiological studies. Plasma ANP has been measured for the asthmatic group during acute severe asthma and at least 4 weeks later while clinically stable as well as for a control group who included 15 clinically free children with appropriate age and sex the mean plasma value of ANP during acute severe asthma [9.25 [2.95 pg/ml] was significantly higher [P<0.001] than the corresponding values of clinically stable asthmatic children [6.13 +/- 2.72 pg/ml] and the control group [1.45 +/- 1.12pg/ml] also the difference between the mean plasma ANP values of clinically stable asthmatic children and the control group was statistically highly significant [p<0.001] we concluded that ANP could be considered one of the mediators of asthma modulation that increased in asthmatic children to protect against bronchoconstriction

Atrial natriuretic peptide in bronchial asthma in children

The hormone atrial natriuretic peptide [ANP] causes bronchodilatation and partially protects against direct and indirect bronchial challenges in patients with asthma. The present study was carried out to determine the role of ANP in bronchial asthma in children. Twenty asthmatic children with age ranged from 1.5 to 11 years old were subjected to clinical, laboratory and radiological studies. Plasma ANP has been measured for the asthmatic group during acute sever asthma and at least 4 weeks later while clinically stable, as well as, for a control group who included 15 clinically free children with appropriate age and sex. The mean plasma value of ANP during acute sever asthma [9.25 +/- 2.95 pg/me was significantly higher [P<0.001] than the corresponding values of clinically stable asthmatic children [6.13 +/- 2.72 pg/ml] and the-control group [1.45 +/- 1.12 pg/ml]. Also, the difference between the mean plasma ANP values of clinically stable asthmatic children and the control group was statistically highly significant [P<0.001]. We concluded that ANP could be considered one of the mediators of asthma modulation that increased in asthmatic children to protect against bronchocontriction